Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Optimization of Spectroscopic Imaging Parameters and Procedures for Prostate at 3 Tesla Using an External Probe

This study has been completed.
Sponsor:
Collaborator:
Cross Cancer Institute
Information provided by (Responsible Party):
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT00314522
First received: April 11, 2006
Last updated: February 23, 2016
Last verified: December 2011

April 11, 2006
February 23, 2016
September 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00314522 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Optimization of Spectroscopic Imaging Parameters and Procedures for Prostate at 3 Tesla Using an External Probe
Optimization of Spectroscopic Imaging Parameters and Procedures for Prostate at 3 Tesla Using an External Probe
This study performed a retrospective analysis of patient images to develop software in determining dose delivered for each fraction treatment.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
primary care clniic
Healthy
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
5
March 2006
Not Provided

Inclusion Criteria:

  • Subject 18 years of age and over
Male
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00314522
EX-0003
Not Provided
Not Provided
Not Provided
AHS Cancer Control Alberta
AHS Cancer Control Alberta
Cross Cancer Institute
Principal Investigator: Gino Fallone, PhD AHS Cancer Control Alberta
AHS Cancer Control Alberta
December 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP